Winnipeg – TheNewswire – February 12, 2024 – Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to announced that it has completed research and development of its OvaPhage product, and is preparing to conduct field trials in Canada as a final step before commercialization. Cytophage has been in longstanding discussions with Canadian industry leaders who have sought alternatives to the currently available disinfectant products used in egg production. As a result, Cytophage has developed OvaPhage, its next product in the FarmPhage line. OvaPhage is a bacteriophage product that will address bacteria such as Salmonella, Escherichia, and Shigella on the surface of eggs. OvaPhage is a disinfectant bacteriophage product that, in laboratory studies, reduces 90% of bacterial load on egg shells. OvaPhage is also environmentally friendly, non-toxic and does not damage the cuticle of the egg.
温尼伯–美通社–2024 年 2 月 12 日–Cytophage 科技有限公司（多伦多证券交易所股票代码：CYTO）（以下简称 “Cytophage “或 “公司”）欣然宣布，公司已完成 OvaPhage 产品的研发工作，并准备在美国进行现场试验。(多伦多证券交易所股票代码：CYTO）（以下简称 “Cytophage “或 “公司”）欣喜地宣布，公司已完成 OvaPhage 产品的研发工作，并准备在加拿大进行现场试验，这是商业化之前的最后一步。Cytophage 一直在与加拿大行业领导者进行长期讨论，这些领导者一直在寻求鸡蛋生产中使用的现有消毒剂产品的替代品。因此，Cytophage 开发出了 FarmPhage 系列的下一个产品 OvaPhage。OvaPhage 是一种噬菌体产品，可消灭鸡蛋表面的沙门氏菌、埃希氏菌和志贺氏菌等细菌。OvaPhage 是一种消毒噬菌体产品，在实验室研究中，它能减少蛋壳上 90% 的细菌量。OvaPhage 还具有环保、无毒的特点，不会损坏鸡蛋的角质层。
Cytophage developed OvaPhage based on its proprietary bacteriophage technology, and has tested it in its laboratories over the past 9 months. Cytophage is now preparing for field trials which will involve testing the product in poultry barns. OvaPhage will be sprayed on the eggs using the existing closed spray systems available in poultry barns. The Company’s national poultry advisor has indicated that Canadian egg producers would welcome new products that will decrease spoilage and increase revenues while not requiring new application processes.
Cytophage 以其专有的噬菌体技术为基础开发了 OvaPhage，并在过去 9 个月中在其实验室进行了测试。 目前，Cytophage 正准备进行实地试验，包括在禽舍中测试该产品。 OvaPhage 将使用禽舍现有的封闭式喷洒系统喷洒在鸡蛋上。 公司的全国家禽顾问表示，加拿大的鸡蛋生产商将欢迎既能减少变质、增加收入，又不需要新的应用程序的新产品。
To facilitate this step, an Experimental Studies Certificate application is being prepared for submission to the Canadian Food Inspection Agency. An application for regulatory approval in the United States has been submitted and a similar regulatory approval submission for Canada is currently being developed. Upon completion of field testing and regulatory approvals, the Company expects to commence commercialization of OvaPhage across Canada.
为便于完成这一步骤，目前正在准备向加拿大食品检验局提交实验研究证书申请。 美国的监管审批申请已经提交，加拿大的类似监管审批申请目前正在制定中。 在完成现场测试和监管审批后，公司预计将在加拿大全国范围内开始 OvaPhage 的商业化。
“OvaPhage is one of several product developments that Cytophage aims to commercialize in 2024 with our proprietary bacteriophage technology,” said Dr Steven Theriault, CEO of Cytophage. “Canada is a global leader in maximizing egg production. We believe that the successful field testing and commercialization of OvaPhage in Canada will strongly position the product for distribution across the globe. We look forward to providing continued updates as to additional bacteriophage products and applications in both animal health and human health”
“OvaPhage是Cytophage公司利用我们专有的噬菌体技术于2024年实现商业化的几项产品开发之一，”Cytophage公司首席执行官Steven Theriault博士说。”加拿大在最大限度提高鸡蛋产量方面处于全球领先地位。 我们相信，OvaPhage 在加拿大的成功现场测试和商业化将为该产品在全球的销售奠定坚实的基础。我们期待着继续提供有关更多噬菌体产品以及在动物健康和人类健康领域应用的最新信息。
For media inquiries: 媒体垂询：
Heather Medwick
President 主席
heather@cytophage.com
431 388 8873
About Cytophage: 关于细胞噬菌体
Cytophage is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization. Committed to addressing the global challenge of antibiotic resistance, Cytophage advances innovative products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security.
Cytophage 是一家致力于噬菌体研究、产品开发和商业化的先锋生物技术公司。Cytophage 致力于应对抗生素耐药性这一全球性挑战，不断推出创新产品，利用噬菌体的力量来抗击影响人类健康、动物健康和食品安全的细菌感染。
Cautionary Statement on Forward-Looking Information
关于前瞻性信息的警示声明
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Cytophage to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Cytophage’s Filing Statement dated January 30, 2024, which is available for view on SEDAR+ at www.sedarplus.ca. These risks include but are not limited to, the risks associated with the bacteriophage industry, such as operational risks in development or capital expenditures, the uncertainty of extensive regulatory approval requirements, government regulations, protection of intellectual property, product liability and rapid technological advancements. Forward-looking statements contained herein are made as of the date of this press release, and Cytophage disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV)
本新闻稿包含适用的加拿大证券法定义的 “前瞻性信息 “和 “前瞻性陈述”（统称 “前瞻性陈述”）。除历史事实陈述外，所有陈述均为前瞻性陈述，均基于截至本新闻稿发布之日的预期、估计和预测。计划”、”预算”、”预测”、”估计”、”相信 “或 “打算 “等词语或这些词语和短语的变体，或声明某些行动、事件或结果 “可能 “或 “可以”、”将会”、”可能 “或 “将要 “发生或实现）不是历史事实的陈述，可能是前瞻性陈述。前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，可能导致Cytophage的实际结果、业绩或成就与前瞻性陈述明示或暗示的任何未来结果、业绩或成就存在实质性差异。Cytophage公司2024年1月30日的备案声明中 “风险因素 “标题下描述了可能导致实际结果与这些前瞻性声明中预期的结果存在实质性差异的因素，该声明可在SEDAR+网站上查阅：www.sedarplus.ca。这些风险包括但不限于与噬菌体行业相关的风险，如开发或资本支出中的运营风险、大量监管审批要求的不确定性、政府法规、知识产权保护、产品责任和快速的技术进步。除法律要求外，Cytophage不承担因新信息、结果、未来事件、情况或管理层的估计或观点发生变化或其他原因而更新任何前瞻性声明的义务。我们无法保证前瞻性声明的准确性，因为实际结果和未来事件可能与前瞻性声明中的预期大相径庭。因此，提醒读者不要过分依赖前瞻性声明。多伦多证券交易所及其监管服务提供商（该术语在多伦多证券交易所政策中定义）